Evaluation of nasal and blood eosinophilia in children suffering from perennial allergic rhinitis treated with beclomethasone dipropionate.
In 16 children suffering from allergic rhinitis, and treated with intranasal Beclomethasone Dipropionate (BDP) for 3 months, therapy significantly diminished the number of nasal eosinophils, while it did not cause any change in blood eosinophilia. This may confirm the local effect of this drug, given at 300 microgram/die. The reduction of nasal eosinophilia during BDP therapy can be explained by the attenuation of the tissue damage characterized by allergic inflammation. The release of mediators, particularly histamine, increases epithelial permeability and promotes penetration of the high molecular weight allergens which thereby gain access to submucosal mast cells. Further release of mediators makes the mucosa more and more permeable to allergen entry. BDP decreases mucous permeability and allergen absorption, so reducing inflammation and consequently the migration of eosinophils to the sites of the allergic reaction.
D000281:Administration, Intranasal; D000293:Adolescent; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004802:Eosinophilia / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D009297:Nasal Mucosa / Q000473:pathology; D012221:Rhinitis, Allergic, Perennial / Q000097:blood / Q000188:drug therapy / Q000473:pathology*
D001507:Beclomethasone